CL2023000061A1 - Macrociclos y su uso - Google Patents

Macrociclos y su uso

Info

Publication number
CL2023000061A1
CL2023000061A1 CL2023000061A CL2023000061A CL2023000061A1 CL 2023000061 A1 CL2023000061 A1 CL 2023000061A1 CL 2023000061 A CL2023000061 A CL 2023000061A CL 2023000061 A CL2023000061 A CL 2023000061A CL 2023000061 A1 CL2023000061 A1 CL 2023000061A1
Authority
CL
Chile
Prior art keywords
macrocyclic compounds
macrocycles
cancer
present disclosure
methods
Prior art date
Application number
CL2023000061A
Other languages
English (en)
Inventor
Jean Cui Jingrong
Original Assignee
Blossomhill Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blossomhill Therapeutics Inc filed Critical Blossomhill Therapeutics Inc
Publication of CL2023000061A1 publication Critical patent/CL2023000061A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Abstract

La presente descripción se refiere a compuestos macrocíclicos, composiciones farmacéuticas que contienen compuestos macrocíclicos y métodos para usar compuestos macrocíclicos para tratar enfermedades, como el cáncer.
CL2023000061A 2020-07-10 2023-01-06 Macrociclos y su uso CL2023000061A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063050559P 2020-07-10 2020-07-10
US202163143569P 2021-01-29 2021-01-29
US202163217950P 2021-07-02 2021-07-02

Publications (1)

Publication Number Publication Date
CL2023000061A1 true CL2023000061A1 (es) 2023-11-17

Family

ID=79552077

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000061A CL2023000061A1 (es) 2020-07-10 2023-01-06 Macrociclos y su uso

Country Status (12)

Country Link
US (1) US20230257396A1 (es)
EP (1) EP4178958A1 (es)
JP (1) JP2023532946A (es)
KR (1) KR20230037564A (es)
CN (1) CN116171279A (es)
BR (1) BR112023000463A2 (es)
CA (1) CA3187834A1 (es)
CL (1) CL2023000061A1 (es)
IL (1) IL299732A (es)
MX (1) MX2023000503A (es)
TW (1) TW202216730A (es)
WO (1) WO2022011123A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023133375A1 (en) * 2022-01-05 2023-07-13 Blossomhill Therapeutics, Inc. Macrocyclic compounds and use as kinase inhibitors
WO2023240140A1 (en) * 2022-06-08 2023-12-14 Blossomhill Therapeutics, Inc. Indazole macrocycles and their use
WO2024016986A1 (zh) * 2022-07-21 2024-01-25 贝达药业股份有限公司 大环化合物及其药物组合物和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014022106B1 (pt) * 2012-03-06 2022-08-02 Pfizer Inc Derivados macrocíclicos, combinação, composição e usos na fabricação de um medicamento para o tratamento de doenças
KR20150127249A (ko) * 2013-03-13 2015-11-16 보스톤 바이오메디칼, 인크. 암 치료를 위한 암 줄기세포 경로 키나아제의 저해제로서 3-(아릴 또는 헤테로아릴)메틸렌인돌린-2-온 유도체
EA031863B1 (ru) * 2014-01-24 2019-03-29 ТиПи ТЕРАПЬЮТИКС, ИНК. Диарильные макроциклы в качестве модуляторов протеинкиназ
JOP20190213A1 (ar) * 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1

Also Published As

Publication number Publication date
US20230257396A1 (en) 2023-08-17
CN116171279A (zh) 2023-05-26
KR20230037564A (ko) 2023-03-16
JP2023532946A (ja) 2023-08-01
WO2022011123A1 (en) 2022-01-13
EP4178958A1 (en) 2023-05-17
BR112023000463A2 (pt) 2023-03-28
TW202216730A (zh) 2022-05-01
MX2023000503A (es) 2023-02-09
IL299732A (en) 2023-03-01
CA3187834A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CL2023000061A1 (es) Macrociclos y su uso
CO2020003714A2 (es) Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostéricos
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
CL2022001671A1 (es) Inhibidores de sos1
CO2020005887A2 (es) Compuestos policíclicos como inhibidores alostéricos de shp2
ECSP20021913A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2020000633A2 (es) Compuestos macrocíclicos y usos de los mismos
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
GT200500237A (es) Derivados de pirimidina
ECSP15035343A (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa pim
DOP2011000361A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cancer y otras enfermedades
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
CR11200A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k
CL2010000320A1 (es) Un compuesto 8-(1,3-dihidro-isoindol-2-ilmetil)-2,9-dihidro-1,2,7,9-tetraaza-fenalen-3-ona, como inhibidor de parp; composicion farmaceutica; y su uso para el tratamiento del cancer.
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
CR11201A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY36702A (es) Piridinas sustituidas y métodos de uso
UY39574A (es) Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene
CO2022008817A2 (es) Macrociclos para uso en el tratamiento de enfermedades
CO2022000481A2 (es) Inhibidores de enzimas
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
CO2020003475A2 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos